Over the past 10 years, evidence emerged that opioid analgesics, especially at high doses or when combined with sedative hypnotics, are associated with opioid-related harms, including opioid overdose death.1 Studies have also raised questions regarding efficacy; for instance, the SPACE trial found that opioids were not better than nonopioid medications for improving pain-related function among 240 opioid-naive patients with moderate to severe chronic back pain or hip or knee osteoarthritis pain.2 This evidence has guided efforts to promote opioid tapering for patients receiving long-term opioid therapy based on the assumption that removing a treatment without proven benefit and known harms would improve outcomes.
Larochelle M, Lagisetty PA, Bohnert ASB. Opioid Tapering Practices—Time for Reconsideration? JAMA. 2021;326(5):388–389. doi:10.1001/jama.2021.11118
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: